Patients as Partners in Research Focus Group
The CMTA is pleased to announce the launch of our Patients as Partners in Research initiative! The goal of Patients as Partners in Research is to advance the work of our Strategy to Accelerate Research (STAR) and showcase ways the patient community can participate in the critical work of furthering the development of treatments, and ultimately a cure, for CMT.
One of the first projects belonging to our new research initiative is the establishment of a Patients as Partners in Research Focus Group. In partnership with the Cambridge, Massachusetts-based biopharmaceutical company Acceleron Pharma, the CMTA will bring together patients to participate in a focus group following the upcoming CMTA Patient/Family Conference in New Jersey on June 16. Sign up now …
The Winter 2018 CMTA Report
In this issue: OT/PT Conference, Pilates, Balance Walking, Foot Surgery, Scootering and more …
Breakthroughs to a Cure
Thanks to your support of the CMTA’s research initiative, promising therapeutic approaches for CMT1A have been identified. Studies in two laboratory models of CMT1A not only stopped progression of the disease, but also showed improvement of some symptoms. And, while the 1A project is furthest along the path to drug delivery, projects addressing 90% of all cases of CMT, including types 1B, 1X, 2A, 2E and 4, are also delivering promising results using cutting-edge techniques. To deliver the first treatments for CMT, we need funding for clinical trials and further drug development. Learn more…
Register Now for CMTA Camp Footprint 2018!
We are excited to announce that registration is now OPEN for Camp Footprint 2018, the only summer camp in the United States just for kids ages 10-18 with CMT! (If you are 19 or older and would like to make an impact on the lives of children living with CMT, we encourage you to apply to be a volunteer!) Learn more and register now …
CMT1A Research Breakthrough!
Scientists at Ionis Pharmaceuticals, in collaboration with the Charcot-Marie-Tooth Association, have identified a promising early-stage therapeutic approach with antisense technology for CMT Type 1A (CMT1A), the most common form of the disease, accounting for half of all cases. Read more …
Studies in two laboratory models of CMT1A not only stopped progression of the disease, but also showed improvement of some symptoms. To deliver the first treatments for CMT1A and other types of CMT, we need funding for clinical trials and further drug development.
Charcot-Marie-Tooth, or CMT, is the most commonly inherited peripheral neuropathy and affects an estimated 2.8 million people.
The CMTA has over 80 Branches across North America to support people with CMT, raise awareness, and fund research. Connect with your nearest Branch today!
Without fundraising and community volunteers, the CMTA would not be the leading force in CMT Research that it is today. Are you ready to make an impact?
Visit our store to see some of the most fun and fashionable ways to raise awareness!